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Objective: TGF-b is synthesized in an inactive latent complex that is unable to bind to membrane
receptors, thus unable to induce a cellular biological response until it has been activated. In addition to
activation by chemical mediators, recent studies have demonstrated that mechanical forces may activate
latent TGF-b via integrin-mediated cellular contractions, or mechanical shearing of blood serum. Since
TGF-b is present in synovial ﬂuid in latent form, and since normal diarthrodial joint function produces
ﬂuid shear, this study tested the hypothesis that the native latent TGF-b1 of synovial ﬂuid can be acti-
vated by shearing.
Design: Synovial ﬂuid from 26 bovine joints and three adult human joints was sheared at mean shear
rates up to 4000 s1 for up to 15 h.
Results: Unsheared synovial ﬂuid was found to contain high levels of latent TGF-b1 (4.35  2.02 ng/mL
bovine, 1.84  0.89 ng/mL human; mean  radius of 95% conﬁdence interval) and low amounts
(<0.05 ng/mL) of the active peptide. Synovial ﬂuid concentrations of active TGF-b1 increased mono-
tonically with shear rate and shearing duration, reaching levels of 2.64  1.22 ng/mL for bovine and
0.60  0.39 ng/mL for human synovial ﬂuid. Following termination of shearing, there was no statistical
change in these active levels over the next 8 h for either species, demonstrating long-term stability of the
activated peptide. The unsheared control group continued to exhibit negligible levels of active TGF-b1 at
all times.
Conclusions: Results conﬁrmed the hypothesis of this study and suggest that shearing of synovial ﬂuid
might contribute an additional biosynthetic effect of mechanical loading of diarthrodial joints.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Transforming growth factor beta (TGF-b) is a ubiquitous multi-
functional cytokine thatmodulates the proliferation, differentiation
and extracellular matrix (ECM) production of various biological
tissues1. While most cells express TGF-b receptors2,3, there has
been particular interest in its role in the development and main-
tenance of diarthrodial joints due to the high native levels of TGF-
b in cartilage4e6 and the surrounding synovial ﬂuid7e9. Traditional
investigations into the regulation of TGF-b signaling in cartilage
have focused primarily on characterizing its synthesis, and its
inﬂuence on the metabolic activity of chondrocytes. These studies
have typically shown that TGF-b can greatly impact biosynthesis by: G.A. Ateshian, Department
00 West 120th Street, 220
States. Tel: 1-212-854-8602;
hian).
s Research Society International. Pchondrocytes10e14 and that its production is regulated by a variety
of mechanical8,15 and chemical factors5.
In cartilage, as in other tissues, TGF-b is synthesized in an
inactive latent complex that is unable to bind to membrane
receptors, thus unable to induce a cellular biological response
until it has been activated. In this latent complex, the mature
TGF-b 25 kDa peptide is linked non-covalently to a 70 kDa latency
associated peptide (LAP), together forming the small latent
complex (SLC). This complex may be disulﬁde-bonded to a latent
TGF-b binding protein (LTBP, w180 kDa), constituting a conﬁgu-
ration termed the large latent complex (LLC)16,17. In growth plate
cartilage, both SLC and LLC are secreted by chondrocytes; the LLC
can bind to the ECM via the LTBP18,19. In synovial ﬂuid, latent
TGF-b likely resides in an unbound soluble form. In order to elicit
a biological response, the mature TGF-b peptide must ﬁrst be
released from the LAP in a process termed TGF-b activation16,17.
Although this process is essential for TGF-b signaling, only a few
studies have investigated potential activation mechanisms in
cartilage and synovial ﬂuid.ublished by Elsevier Ltd. All rights reserved.
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tissues have shown that TGF-b activation can occur through
a variety of chemical mediators, including proteases such as
plasmin20 and matrix metalloproteinases (MMPs)21, thrombo-
spondin (TSP)22, and reactive oxygen species23. It is generally
believed that activation mechanisms are tissue-speciﬁc and for any
given tissue, several mechanisms may be involved17. In arthritic
synovial ﬂuid, it has been suggested that metalloproteinases may
be responsible for the activation of TGF-b24. Studies in cartilage
have shown that matrix-bound latent TGF-b can be activated by
stromelysin-1 (MMP-3)25 and collagenase-3 (MMP-13)26 released
from cellular matrix vesicles during endochondral ossiﬁcation, and
by transglutaminase in aging articular cartilage27.
In addition to activation by chemical mediators, recent studies
have demonstrated that mechanical forces may also activate latent
TGF-b28. This concept was originally demonstrated in a study by
Wipff et al.29, where integrin-mediated cellular contractions were
shown to pull on matrix-bound latent TGF-b to induce activation.
Subsequently, in a study by Ahamed et al.30, mechanical shearing of
blood serumwas shown to activate soluble TGF-b. It is believed that
these mechanically-induced activation mechanisms may play an
important role in physiologic processes such as wound healing.
Although this mechanism has only been described in a few
tissue systems, mechanically-induced TGF-b activation may
potentially play an important physiologic role in any tissue that
contains latent TGF-b and is subjected to large repetitive mechan-
ical loads. In the case of diarthrodial joints, in addition to the well
recognized cyclic compression experienced by cartilage, synovial
ﬂuid is subjected to reciprocal shearing between sliding articular
surfaces. During routine physiologic joint motion, the shear rate of
synovial ﬂuid can reach levels more than 10 times those achieved in
arterial blood ﬂow31.
Based on this understanding, the objective of this experimental
study was to test the hypothesis that shearing of synovial ﬂuid can
activate its native latent TGF-b. To test this hypothesis, synovial
ﬂuid was subjected to continuous in vitro shearing at rates that
approach physiologic levels, and the active concentration of
TGF-b1 was measured over time. Mature and immature bovine
synovial ﬂuid was used to explore the dependence of activation on
ﬂuid shear rate and adult human synovial ﬂuid was used to
conﬁrm the physiologic relevance of this mechanism. Further-
more, an additional test was conducted to assess the stability of
this freshly activated TGF-b based on the traditional under-
standing that TGF-b has a short in vivo half-life due to its inter-
actions with a variety of non-speciﬁc binding proteins32,33. Since
recombinant latent TGF-b is commercially available in the SLC,
shear activation of the exogenous SLC in synovial ﬂuid was also
investigated.
Methods
Materials
Active TGF-b strongly binds and adheres to plasticware34 due to
its high degree of hydrophobicity, making it potentially difﬁcult to
accurately measure its concentration in vitro. Therefore, only
materials which exhibited negligible binding to TGF-bwere used in
this study (see Supplementary Data). To this end, synovial ﬂuid was
sheared inside Tygon tubing (Saint-Gobain Corporation, www.
tygon.com) and collected and stored in silanized Eppendorf tubes
(www.eppendorf.com) before and after testing. Synovial ﬂuid was
aspirated from the carpometacarpal joints of 2-month-old imma-
ture (N ¼ 8 joints) and 6-year-old adult (N ¼ 22 joints) bovines
supplied by a local slaughterhouse (Green Village Packing Co., NJ).
After acquisition, all bovine specimens were decellularized throughcentrifugation (3000g, 20 min). For each source, synovial ﬂuid
samples were generated by pooling the ﬂuid from two individual
joints, producing four samples for immature synovial ﬂuid and 11
samples for mature synovial ﬂuid. Each sample was divided into
multiple 1.5 mL aliquots and stored at 30C until testing.
Human synovial ﬂuid was obtained and frozen from three
autopsydonors (ages57, 59, and61years, 4mLperdonor),within8h
postmortem through the National Disease Research Interchange
(NDRI). These specimens were ﬁltered through a polyester mesh
(100 mm) to remove debris, butwerenot subjected to centrifugation.
At the completion of testing, all synovial ﬂuid samples were
collected, ﬂash frozen in a bath of ethanol with dry ice, and stored
at 30C until subsequent ELISA analysis.
Synovial ﬂuid shearing: temporal response
Synovial ﬂuid was injected into Tygon tubing (R-3603, 1/32" ID)
and subjected to continuous circulation at a prescribed ﬂow rate
(see below) with a peristaltic pump or maintained uncirculated as
a control group. The process of circulating a viscous ﬂuid in a tube
produces shearing as a result of frictional interactions with the
inner tube wall. For a Newtonian ﬂuid, the shear rate increases
linearly along the radial direction of the tube, starting from zero at
the centerline. Though synovial ﬂuid is not a Newtonian ﬂuid, an
estimate of themean shear ratewas obtained under the simplifying
assumption of Newtonian behavior. Accordingly, the pump speed
was prescribed to maintain mean shear rates based on
HagenePoiseuille law. Adult bovine synovial ﬂuid was subjected to
shear rates of 0, 600, 1700, or 4000 s1, each for a duration of 2, 7,
and 15 h. This test was conducted with four synovial ﬂuid samples
for each group, using 12 aliquots (four shear rates  three time
points) from each sample.
Immature bovine synovial ﬂuid was subjected to shear at
4000 s1 or maintained uncirculated for a duration of 2, 7, and 15 h.
This test was conducted with four synovial ﬂuid samples for each
group, using six aliquots (two shear rates  three time points) from
each sample.
For human synovial ﬂuid testing, each donor specimen was
subjected to shear at 3750 s1 or maintained uncirculated (2 mL
each). Here, small aliquots were collected immediately before, then
after 2 and 8 h of testing.
Though experiments were conducted at room temperature,
continuous shearing of synovial ﬂuid over several hours produced
an increase in its temperature, especially at the higher shear rates.
Measurements determined that for all bovine synovial ﬂuid
samples, the peak temperature never exceeded 37C. All control
(unsheared) samples were maintained at 37C. For human synovial
ﬂuid testing, the temperature approached 41C for part of the test.
However, preliminary studies in adult bovine synovial ﬂuid (n ¼ 3
samples each at 37, 45, and 56C) showed that this slightly elevated
temperature for up to 8 h does not produce any alterations to active
and total TGF-b levels (Fig. 1).
Synovial ﬂuid shearing: SLC
It has been shown that chondrocytes secrete latent TGF-b in the
SLC form18,19, suggesting it may also be present in synovial ﬂuid.
Since recombinant SLC is readily available, an additional test was
conducted to independently assess whether it will similarly
undergo shear-induced activation in synovial ﬂuid. Here, adult
bovine synovial ﬂuid was supplemented with 35 ng/mL of human
recombinant SLC-conﬁgured latent TGF-b1 (R&D Systems). This
concentration of exogenous latent TGF-b is an order of magnitude
higher than the endogenous levels in synovial ﬂuid (see Results)
allowing for the assessment of exogenous SLC latent TGF-b1
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Fig. 1. Effect of temperature on the stability of latent TGF-b1 in synovial ﬂuid. Concentration of (A) active and (B) total TGF-b1 in adult bovine synovial ﬂuid after exposure to various
temperatures for up to 15 h. All TGF-b1 is initially in the latent form and is stable at all temperatures for up to 7 h. After 15 h at 56C, all TGF-b1 is degraded except for a small
fraction that remains in the active form (n ¼ 3 sample per temperature group; mean  radius of 95% conﬁdence interval).
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Fig. 2. Apparent concentration of shear-activated TGF-b1 in synovial ﬂuid after various
amounts of dilution (mean  radius of 95% conﬁdence interval). Concentrations are
corrected for the DF then normalized to the value evaluated at the highest dilution.
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sheared at 1700, 4000 s1 or maintained unsheared for 0.5, 2, or
7 h. This test was conducted with three samples for each group,
using nine aliquots (three shear rates  three time points) from
each sample.
Synovial ﬂuid shearing: protease inhibition
An additional test was conducted to preclude the action of
proteases in activating latent TGF-b. Adult bovine synovial ﬂuidwas
either supplemented with protease inhibitors (Complete Cocktail
1 w/EDTA, Roche) or maintained as an untreated control group.
Both groups were subjected to continuous shearing at 4000 s1 for
7 h. This testwas conductedwith four samples for each group, using
one aliquot (one shear rate  one time point) from each sample.
Stability of activated TGF-b
A ﬁnal test was conducted to explore the stability of TGF-b1 after
its activation in synovial ﬂuid.
Sheared synovial ﬂuid from the previously completed tests
(adult bovine synovial ﬂuid 15 h at 4000 s1, human synovial ﬂuid
8 h at 3750 s1, SLC supplemented adult bovine synovial ﬂuid 7 h at
4000 s1; three samples from each) was transferred to a silanized
Eppendorf tube and maintained unsheared for an additional 8-h
period at 37C. During this period, a small aliquot from each
group was collected after 0, 2, and 8 h.
Enzyme-linked immunosorbant assay (ELISA)
Tested synovial ﬂuid aliquots were thawed and the concentra-
tion of active TGF-b1 was measured in duplicate with a TGF-b1
ELISA kit (R&D Systems), using recombinant human TGF-b1 as
standards. Only active TGF-b1 can be detected by this ELISA kit.
Therefore, in order to also measure total TGF-b1 in synovial ﬂuid,
samples were subsequently subjected to an acid activation treat-
ment consisting of acidiﬁcation for 15 min with 20% of 1 N HCl,
followed by neutralization with an equal volume of 1.2 N NaOH/
0.5 M HEPES, and a second ELISA analysis. This is a routine proce-
dure for activating all latent TGF-b1 in biological samples, allowing
for the measurement of their total TGF-b1 content18,35. This
measure accounted for the low but non-negligible levels of latent
TGF-b1 in the R&D Systems serum-based Reagent Diluent.Preliminary tests suggested that ﬂuid samples of high viscosity
exhibit suppressed TGF-b levels when assayed through ELISA.
Although synovial ﬂuid is highly viscous, this issue was not
explicitly addressed in previous reports on TGF-b concentrations in
synovial ﬂuid. Therefore, a preliminary testwas conducted to assess
the effect of diluting synovial ﬂuid samples on mitigating this
effect. The TGF-b1 content of sheared adult bovine synovial ﬂuid
(2 h, 4000 s1) was measured after dilution in Reagent Diluent at
dilution factors (DF) of 1, 2.5, 5, 10, 20, 40, 80. At each dilution,
measured ELISA concentration was multiplied by the DF and
normalized to the value obtained at 80 DF. Results demonstrate that
diluting synovial ﬂuid increases its apparent TGF-b1 concentration
(Fig. 2). At higher dilutions, this increase levels off to the actual
concentration in synovial ﬂuid. In effect, undiluted synovial ﬂuid
yields a measure of only 20% of this actual concentration. Subse-
quently, a minimum DF of 10 was adopted for all ELISA measure-
ments in this study, due to its yield of 80% of the actual TGF-b1
concentration.
Statistical analysis
In each study, one statistical analysis was performed on the
concentrations of active TGF-b1 and another on the total
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way analysis of variance (ANOVA) was performed, with a ¼ 0.05
and statistical signiﬁcance set at P < 0.05, to determine the effects
of shearing rate and testing duration, using repeated measures for
both factors since aliquots from the same sample were used for
each cell (n ¼ 4 samples in each cell). For the adult bovine synovial
ﬂuid, a post-hoc power analysis for this design indicated an ach-
ieved power of nearly 100% for detecting differences in active TGF-
b1 concentrations and 11% for detecting differences in total TGF-b1
concentrations. For the protease inhibition study, a paired two-
tailed Student’s t test was used, with a ¼ 0.05, to detect differ-
ences between the two tested groups, with aliquots from the same
sample used in each group (n ¼ 4 samples). A post-hoc power
analysis indicated an achieved power of 14% for detecting differ-
ences. Two-way ANOVA was also used for the SLC study and the
study on the stability of activated TGF-b1.Results
Synovial ﬂuid shearing: temporal response
Prior to shearing, high levels of total TGF-b1 were measured in
synovial ﬂuid (4.35  2.02 ng/mL adult bovine, 3.66 1.12 immature
bovine, 1.84  0.89 ng/mL human; mean  radius of 95% conﬁdence
interval). However, at all time points under control (unsheared)
conditions, negligible TGF-b1 levels were detected in synovial ﬂuid
(0.01  0.03 ng/mL in adult bovine, 0.05  0.2 ng/mL in immature
bovine, and 0.03 0.03 ng/mL in human), indicating that TGF-b1was
predominantly in a latent form. Similar levels of active TGF-b1
(0.01  0.02 ng/mL, n ¼ 3 samples) were detected in adult bovine
synovial ﬂuid before freezing as well, indicating that freezing had no
effect onactivation.Under continuous shearing, active TGF-b1 in adult
bovinesynovialﬂuidwasobserved to increase signiﬁcantly (P<0.001)
with time and shearing rate; adult bovine synovial ﬂuid reached
a value of 2.641.22 ng/mL [Fig. 3(A)] and immature bovine synovial
ﬂuid reached 2.73  0.56 ng/mL [Fig. 4(A)] after 15 h at the highest
shear rate (4000 s1). Similarly, for human synovial ﬂuid, shearing at
3750 s1 activated 0.60  0.39 ng/mL of TGF-b1 after 8 h [Fig. 5(A)].
Furthermore, forallgroupsandshearingconditions, theconcentration
of total TGF-b1 did not change over time (P ¼ 0.95 adult bovine;
P¼ 0.88 immature bovine; P¼ 0.94 human, Figs. 3(B), 4(B) and 5(B)).Synovial ﬂuid shearing: SLC
For this experiment, exogenous SLC content was determined by
measuring total content and subtracting native levels (average0
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Fig. 3. Concentration of (A) active and (B) total TGF-b1 in adult bovine synovial ﬂuid unde
interval). *P < 0.001, þP ¼ 0.002 indicate statistical increase above corresponding control tconcentrations assessed from prior tests), yielding 36.9 2.5 ng/mL
for the initial (unsheared) content. Exogenous active content was
similarly assessed. When reporting results, total and active exoge-
nous TGF-b1 concentrations are expressed as a fraction of this
initially supplemented exogenous concentration. Initially, and in
the absence of shearing, exogenous TGF-b1 was nearly entirely in
its latent form, as indicated by an active fraction of 0.012  0.011.
The active level of exogenous TGF-b1 increased signiﬁcantly with
time and shearing rate [Fig. 6(A)], reaching an active fraction of
0.67  0.61 after 7 h at 4000 s1. Furthermore, under all shearing
conditions, the concentration of total TGF-b1 did not change over
time [P ¼ 0.96, Fig. 6(B)].Synovial ﬂuid shearing: protease inhibition
The inhibition of protease activity in synovial ﬂuid had no effect
on the shear-induced activation of latent TGF-b. No statistical
difference in activated concentrations between protease-inhibitor
treated and control samples was observed in adult bovine syno-
vial ﬂuid after 7 h of shearing (P ¼ 0.36, Table I).Stability of activated TGF-b
For all groups (human, adult bovine, and SLC supplemented
bovine synovial ﬂuid), upon cessation of shearing, no statistical
change to active TGF-b levels was observed over a subsequent 8 h
period (P ¼ 0.91 adult bovine; P ¼ 0.34 human; P ¼ 0.98 SLC sup-
plemented; Fig. 7), indicating that shear-induced activated TGF-b is
stable in synovial ﬂuid.Discussion
It has beenwell established that TGF-b is an important regulator
of the development and maintenance of articular cartilage36.
However, as with most biological tissues, the TGF-b present in
diarthrodial joints is produced as a latent complex that must be
activated in order to induce a biological response7,18. Only a few
studies have characterized the potential physiologic mechanisms
by which this activation occurs, focusing on chemical mediators.
The results of this study demonstrate two new and important
ﬁndings: (1) mechanical shearing of synovial ﬂuid can activate
substantial concentrations of latent TGF-b (Figs. 3e6); and (2) these
activated TGF-b concentrations remain stable in synovial ﬂuid (for
8 h at least, Fig. 7). These results strongly suggest that in vivo
shearing of synovial ﬂuid through physiologic joint motion can0
2
4
6
8
0 5 10 15
Time (h)
To
ta
l T
G
F-
1 
(ng
/m
L)
4000 s-1
control
rgoing continuous circulation at various shear rates (mean  radius of 95% conﬁdence
ime point.
01
2
3
4
0 5 10 15
Time (h)
Ac
tiv
e 
TG
F-
1 
(ng
/m
L)
*
*
*
A
4000 s-1
control
0
2
4
6
0 5 10 15
Time (h)
To
ta
l T
G
F-
1 
(ng
/m
L)
4000 s-1
control
B
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activity of the surrounding articular cartilage.
These results build upon the development of a new perspective
on TGF-b activation in biological tissues which suggests that
mechanical forces may play a role in addition to the traditionally
characterized chemical mediators. Mechanically-induced TGF-b
activation was recently observed in a series of experiments which
showed that, in certain culture systems, activation requires the
presence of integrins as well as a stiff cellular substrate. These
observations suggested that TGF-b peptide release may result from
molecular conformational changes as cells pull on the LTBP29. This
concept of mechanical activation was further advanced in the
recent study by Ahamed et al. which showed that mechanical
shearing of blood serum can also activate TGF-b, without the
intervention of integrin mediators; interestingly, this activation
occurred only for the LLC, not the SLC30. Under continuous shearing,
activation of endogenous TGF-b in serum similarly increased over
time, and was more pronounced at greater shear rates. In serum,
activation has been partially attributed to the shear-induced
exchange of thiol-disulﬁde bonds mediated by platelet-derived
TSP-1 37.
The responses observed with synovial ﬂuid share some simi-
larities with serum, though signiﬁcant differences are also
observed.While the relative amount of SLC and LLC in synovial ﬂuid
has not yet been characterized, it is evident that a large fraction of0.0
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Fig. 5. Concentration of (A) active and (B) total TGF-b1 in human synovial ﬂuid under cont
conﬁdence interval). *P ¼ 0.003 indicates statistical increase above corresponding control tSLC undergoes activation with shearing [Fig. 6(A)], unlike serum. A
precise mechanism for activation in synovial ﬂuid remains to be
veriﬁed. Synovial ﬂuid contains large amounts of hyaluronan
macromolecules which undergo elongation and stretching while
subjected to ﬂuid shearing38; these macromolecules may become
entangled with the latent TGF-b complexes. Since latency is
conferred to TGF-b through non-covalent binding to the LAP
protein17, only a relatively small amount of energy conferred by
such entanglements may be necessary to break this bond via
shearing. Thus, hyaluronan-mediated molecular unfolding may
play a signiﬁcant role in the activation of TGF-b. An alternative
mechanism whereby protease activity may be enhanced by
shearing may be discounted in light of the ﬁnding that protease
inhibitors do not alter the activation response (Table I).
Shear rates in synovial ﬂuid have been calculated from estimates
of the relative sliding speed (typicallyw1e10 mm/s) and ﬂuid ﬁlm
thickness (w103e104 mm) between articular surfaces of a joint31.
Therefore, peak shear rates are typically in the range of 103e105 s1,
and the highest shear rate employed in this study was at the low
end of this range. Therefore, physiologic joint motion may poten-
tially activate even higher levels of TGF-b in vivo. Furthermore,
although active concentrations of the other TGF-b isoforms were
not measured in this study, it is likely that TGF-b2 and TGF-b3 are
similarly activated under synovial ﬂuid shearing, based on their
similar latent conﬁgurations.0.0
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released from ECM vesicles can activate ECM-bound latent TGF-
b25,26. Interestingly, in the present study, active TGF-b was not
detected in synovial ﬂuid at any time under zero shear conditions,
despite the fact that the active form is stable (Figs. 3 and 4), sug-
gesting that protease levels in healthy synovial ﬂuid are not sufﬁ-
ciently elevated for chemical activation to occur. This observation
strongly suggests that shear-induced activation is the dominant
mediator of TGF-b activation in healthy synovial ﬂuid.
The shear-induced activation of TGF-b in synovial ﬂuid is ex-
pected to have an important role on the metabolic activity of
articular cartilage based on a variety of in vivo and in vitro experi-
mental observations. Speciﬁcally, the application of exogenous
active TGF-b has been shown to routinely stimulate the synthesis of
DNA39 and ECM proteins, such as proteoglycans11,12, type II
collagen14,40, superﬁcial zone protein41,42, and cartilage oligomeric
matrix protein (COMP)43, while inhibiting the catabolic actions of
interleukin-1 (IL-1)10, tumor necrosis factor-alpha (TNF-a)44, and
several MMPs45. Additionally, the in vivo inhibition of native TGF-
b in synovial ﬂuid has been shown to induce loss of proteoglycans
in the cartilage matrix46,47. Taken together, these results strongly
suggest that access to TGF-b is a requisite for maintaining the
biochemical content and structural integrity of healthy cartilage. In
particular, due to the close proximity of sheared synovial ﬂuid to
the superﬁcial zone chondrocytes, it is plausible that the most
immediate inﬂuence of shear-activated TGF-b is on the synthesis of
superﬁcial zone protein41. This proximity suggests that there exists
a self-regulating mechanism whereby prolonged joint sliding
motion can induce a replenishment mechanism for this tribologi-
cally beneﬁcial protein.
While the beneﬁcial impact of active TGF-b on diarthrodial
tissues is clear, it should also be noted that the in vivo adminis-
tration of large levels of active TGF-b has been shown to induce
pathological effects associated with osteoarthritis, such as inﬂam-
mation, synovial ﬁbrosis, and the formation of osteophytes48.
Furthermore, high steady state levels of active TGF-b have been
observed in pathological synovial ﬂuid samples7. These resultsTable I
Concentrations of active and total TGF-b1 in protease inhibitor supplemented and
untreated control adult bovine synovial ﬂuid samples after 7 h of continuous
shearing (4000 s1; mean  radius of 95% conﬁdence interval)
Treatment Active TGF-b (ng/mL) Total TGF-b (ng/mL)
Control 1.96  0.51 4.37  1.13
Protease inhibitors 1.70  0.31 4.56  0.76highlight the importance of the regulation of active TGF-b levels in
synovial ﬂuid in order tomaintain healthy diarthrodial joint tissues.
Physiologic shearing may serve this function by activating TGF-b in
synovial ﬂuid during periods of increased joint activity, and thus,
inducing biochemical stimulation while mitigating pathological
effects. The importance of active TGF-b regulation is further
emphasized by cartilage metabolic studies that often demonstrate
that biosynthesis can be optimally stimulated by intermediate
doses of active TGF-b. It is interesting that these optimal active TGF-
b doses are typically in the range of 1e10 ng/mL10,14,39, similar to
the concentrations activated by TGF-b shearing (Fig. 1).
The potential physiologic role of shear-induced TGF-b activation
is further supported through the demonstrated stability of acti-
vated TGF-b in synovial ﬂuid. It should be noted that although
activated TGF-b can reassociate with free LAP, the altered confor-
mations of the activated molecules49 make it unlikely to do so at
physiologic concentration levels50. Regardless, the long-term
stability of activated TGF-b observed in synovial ﬂuid is an unex-
pected outcome, based on the traditional understanding that TGF-b
has an extremely short systemic half-life due to interactions with
proteases and non-speciﬁc binding proteins33. This stability
suggests that once activated, TGF-b is able to diffuse into the
surrounding articular cartilage and inﬂuence the metabolic activity
of chondrocytes, especially in the superﬁcial zone.
It has long been recognized that mechanical stimulation of dia-
rthrodial joints is a requisite formaintaining themetabolic activity of
articular cartilage. Studies have generally shown that cyclic or
dynamic loading of joints enhances protein biosynthesis51while joint
immobilization leads to degradation52, and typically attribute these
effects to a direct mechanotransduction pathway. The results of this
study suggest that an additional biosynthetic effect of mechanical
loading may be mediated by TGF-b activation in the synovial ﬂuid.
Thismechanismwould be consistentwith observations that synovial
ﬂuid from animal joints subjected to exercise will enhance tissue
biosynthesis beyond the levels achieved by synovial ﬂuid from
immobilized joints53. The results of this current investigation further
suggest that theseanabolic effectsmaybean importantmanifestation
of shear-induced activation of latent TGF-b in synovial ﬂuid.
Studies involving humans or animals
The Institutional Review Board of Columbia University (Mor-
ningside Campus) has determined that shear testing of human
synovial ﬂuid samples acquired from a tissue bank does not
constitute human subjects research (IRB-AAAI0406).
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Fig. 7. Stability of shear-activated TGF-b1 levels in (A) adult bovine and human synovial ﬂuid samples and (B) adult bovine samples exogenously supplemented with SLC TGF-b1
(mean  radius of 95% conﬁdence interval). Active TGF-b1 fractions in SLC supplemented samples are normalized to the initial supplemented concentration.
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